Mehmet Türker

Dr. Mehmet Türker

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HOHuseyin Ali Ozturk
Huseyin Ali Ozturk
MKMevlut Koc
Mevlut Koc
RORamazan Azim Azim Okyay
Ramazan Azim Azim Okyay
DODilan Damla Ozturk
Dilan Damla Ozturk
EGErdinc Gulumsek
Erdinc Gulumsek
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagl

Verified
Journal Article
Open access
PDF file
SYSendag Yaslikaya
Sendag Yaslikaya
ŞIşuheda ataş ipek
şuheda ataş ipek
IÇipek balıkçı çiçek
ipek balıkçı çiçek
EAEsra Asarkaya
Esra Asarkaya
HAHatice Asoglu
Hatice Asoglu
IKIsmail Oguz Kara
Ismail Oguz Kara
Background: Desmoid tumors (DT) are rare, locally aggressive neoplasms characterized by an unpredictable clinical course. Although anatomical localization has been associated with tumor behavior, its relationship with systemic inflammatory response remains insufficiently explored. This study aimed to evaluate the impact of tumor localization on systemic inflammatory markers and to investigate CD47 expression in DT. Methods: This retrospective cohort study included 127 patients diagnosed with DT between 2010 and 2023. Demographic, clinicopathological, and laboratory data were collected. Systemic inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), HALP score, and pan-immune-inflammation value (PIV), were calculated. Tumor localization was categorized as trunk, extremity, or head and neck. CD47 expression was evaluated by immunohistochemistry. Results: Tumors were most frequently located in the trunk (50.4%), followed by extremities (40.9%) and head and neck region (8.7%). Significant differences in inflammatory markers were observed according to tumor localization. The head and neck group demonstrated lower neutrophil counts (p = 0.020), NLR (p = 0.009), PLR (p < 0.001), and PIV (p = 0.003), while showing higher PNI (p = 0.043) and HALP scores (p = 0.001) compared to trunk-localized tumors. Additionally, smaller tumors (<49 mm) were associated with lower NLR (p = 0.041) and neutrophil counts (p = 0.015). No detectable CD47 expression was observed in any tumor samples. Conclusions: Anatomical localization is closely associated with distinct systemic inflammatory profiles in patients with DT. These findings suggest that tumor location may influence host immune–inflammatory interactions and contribute to the biological heterogeneity of DT. The absence of CD47 expression indicates that alternative immune-related mechanisms may play a role in DT biology. Easily accessible inflammatory markers may provide valuable insights for risk stratification in clinical practice.

1 January 2023 in Cukurova Medical Journal
Verified
Journal Article
Open access
PDF file
EBErtugrul Bayram
Ertugrul Bayram
BMBURAK METE
BURAK METE
PKPakize İrem Kahramanoğlu
Pakize İrem Kahramanoğlu
EMEbru Melekoglu
Ebru Melekoglu
MTMehmet Türker
Mehmet Türker
IKİ. Oğuz Kara
İ. Oğuz Kara
Purpose: This study aimed to compare the effectiveness and toxicity of neoadjuvant dual Human epidermal growth factor receptor-2 (HER-2) blockade combined with chemotherapy in advanced breast cancer. Materials and Methods: Patients with HER2-positive breast cancer who received trastuzumab (T)+ pertuzumab (P) with weekly neoadjuvant paclitaxel or docetaxel were included in the study. Patients’ age, clinical stage, histological reports, ki-67 index, toxicity profiles, and the state of the pathological and radiological response following neoadjuvant therapy were evaluated. Results: All 40 patients were women (mean age 50.9) and the overall rate of pathological complete responses was 62.5% (25/40). The rates of non-responsive patients and grade 2 neuropathy were statistically significantly higher in the group receiving P+T+Weekly Paclitaxel. When SUV values were analyzed based on hormone positivity, it was found that they decreased dramatically in both groups and were statistically significant. The logistic regression analysis developed to predict the precise response status to therapy was found to be significant. Conclusion: When comparing the agents used in dual HER-2 targeted therapies, patient response rates and toxicity profiles may differ. Ductal carcinoma in situ (DCIS) and molecular subtype were found to be significant variables in the developed logistic regression model.

31 August 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SBSedat Biter
Sedat Biter
EBErtugrul Bayram
Ertugrul Bayram
TKTOLGA KÖŞECİ
TOLGA KÖŞECİ
MİMEHMET CİHAN İÇLİ
MEHMET CİHAN İÇLİ
AAAhmet Melih Arslan
Ahmet Melih Arslan
IKİsmail Oğuz Kara
İsmail Oğuz Kara
Background and Objectives: The modified Glasgow Prognostic Score (mGPS)—a composite of serum C-reactive protein (CRP) and albumin—simultaneously reflects systemic inflammatory activity and nutritional reserve. Its specific prognostic role in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab in the second-line setting has not previously been examined in a large multicentre cohort. The aims of this study are to determine whether baseline mGPS independently predicts overall survival (OS) and progression-free survival (PFS) in this population and whether its discriminatory capacity compares favourably with the International Metastatic RCC Database Consortium (IMDC) risk score. Methods: This multicentre retrospective cohort study included 174 consecutive patients with histopathologically confirmed mRCC who progressed on first-line VEGF-targeted tyrosine kinase inhibitor (TKI) therapy and subsequently received nivolumab monotherapy at six oncology centres in Türkiye between January 2015 and December 2023. Baseline mGPS was calculated from serum albumin and CRP measured within four weeks before treatment initiation. Kaplan–Meier analysis with log-rank testing and Cox proportional-hazards regression were used for survival analyses; discriminatory capacity was quantified using Uno’s concordance (C) statistic. Results: The median follow-up was 24.2 months. The median OS was 44.5, 15.3, and 10.0 months for the mGPS 0, 1, and 2 groups, respectively (log-rank p < 0.0001); the median PFS was 6.7, 4.2, and 2.6 months (p = 0.022). On multivariable analysis, mGPS 2 independently predicted inferior OS (hazard ratio [HR] 3.61, 95% confidence interval [CI] 1.78–7.31; p < 0.001) and PFS (HR 1.87, 95% CI 1.17–2.97; p = 0.008). Uno’s C-statistic for OS was numerically higher for the combined mGPS + IMDC model (0.70) than for either the mGPS (0.66) or IMDC (0.63) alone; these differences were not formally tested and are presented descriptively. Conclusions: Baseline mGPS is a simple, inexpensive, and independent prognostic biomarker in mRCC patients treated with second-line nivolumab, providing discriminatory information that may be complementary alongside IMDC risk stratification. Prospective validation in randomised trials is warranted.

11 April 2025 in American Journal of Therapeutics
Verified
Journal Article
Closed access
ATAli Turker
Ali Turker
MBMahmut Buyuksimsek
Mahmut Buyuksimsek
ITİrEm Kolsuz Turker
İrEm Kolsuz Turker
MTMehmet Türker
Mehmet Türker
İAİRFAN ALİŞAN
İRFAN ALİŞAN

30 September 2026 in Cukurova Medical Journal
Verified
Journal Article
Open access
MKMehmet Mutlu KIDI
Mehmet Mutlu KIDI
MTMehmet Türker
Mehmet Türker
SBSedat Biter
Sedat Biter
MEMelek Ergin
Melek Ergin
TTTugba Toyran
Tugba Toyran
EBErtugrul Bayram
Ertugrul Bayram
Purpose: Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator implicated in the pathogenesis of diffuse large B-cell lymphoma, but the prognostic value of its protein expression is uncertain. We evaluated EZH2 expression and its associations with clinicopathological features and survival.Materials and Methods: We retrospectively studied 50 patients with diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. EZH2 expression was assessed by immunohistochemistry using an H-score and classified as high (≥150) or low (